Longeveron LGVN
NASDAQ LGVN
$0.84 +0.02 (+2.02%)
At close: Aug 21, 2026 · 4:00 PM EDT

Longeveron (LGVN) Interest Expenses (2020 - 2026)

Longeveron (LGVN) posted quarterly Interest Expenses of $770000.0 for Q1 2026, down 41.44% year-over-year from $1.3 million in Q1 2025, and down 9.73% quarter-over-quarter from $853000.0 in Q4 2025.

Longeveron (LGVN) Interest Expenses (2020 - 2026) Analysis & Trends

Longeveron's Interest Expenses history runs 7 years deep, the most recent figure standing at $770000.0 for Q1 2026.

  • In Q1 2026, Interest Expenses fell 41.44% year-over-year to $770000.0; the TTM figure through Mar 2026 stood at $770000.0 (down 41.44% YoY), while the FY2025 annual figure was $1.1 million, down 94.15% from the prior year.
  • Interest Expenses for Q1 2026 stood at $770000.0, down from $853000.0 in the prior quarter.
  • The five-year high for Interest Expenses was $38.0 million in Q1 2023, with the low at -$12000.0 in Q4 2022.
  • The 5-year median for Interest Expenses is $702000.0 (2022), against an average of $2.8 million.
  • The sharpest annual moves came in 2023 and 2024: Interest Expenses jumped 5313.11% in 2023, then slumped 99.41% in 2024.
  • Longeveron's Interest Expenses stood at -$12000.0 in 2022, then soared by 358.33% to $31000.0 in 2023, then surged by 3012.9% to $965000.0 in 2024, then decreased by 11.61% to $853000.0 in 2025, then decreased by 9.73% to $770000.0 in 2026.
  • Business Quant data shows LGVN's Interest Expenses at $770000.0 in Q1 2026, $853000.0 in Q4 2025, and $1.5 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Interest Expense (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 39.74 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 82.05 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -4.89 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 20.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 93.62 Mn
10 Longeveron 26.51 Mn 16.41 Mn 182,000.00 -

Historic Data

Download Data
DateValue
Jun 30, 2026 1.33 Mn
Jun 30, 2026 1.33 Mn
Mar 31, 2026 770,000.00
Mar 31, 2026 770,000.00
Dec 31, 2025 853,000.00
Dec 31, 2025 853,000.00
Sep 30, 2025 1.47 Mn
Sep 30, 2025 1.47 Mn
Jun 30, 2025 1.41 Mn
Jun 30, 2025 1.41 Mn
Mar 31, 2025 1.32 Mn
Mar 31, 2025 1.32 Mn
Dec 31, 2024 965,000.00
Dec 31, 2024 965,000.00
Sep 30, 2024 224,000.00
Sep 30, 2024 224,000.00
Jun 30, 2024 47,000.00
Jun 30, 2024 47,000.00
Mar 31, 2024 224,000.00
Mar 31, 2024 224,000.00